Urinary bladder lesions after the Chernobyl accident: Immunohistochemical assessment of p53, proliferating cell nuclear antigen, cyclin D1 and p21(WAF1/Cip1)

Japanese Journal of Cancer Research

Volumn 90, Issue 2, 1999, Pages 144-153

  Romanenko, Alina ^a   Lee, Chyi Chia R ^b   Yamamoto, Shinji ^b   Hori, Taka Aki ^b   Wanibuchi, Hideki ^b   Zaparin, Wadim ^a   Vinnichenko, Wladimir ^a   Vozianov, Alexander ^a   Fukushima, Shoji ^b  

^a STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle; Cyclin D1; p21(WAF1 Cip1); p53; Urinary bladder cancer

Indexed keywords

CESIUM 137; CYCLIN D1; CYCLINE; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUCOSA; CHERNOBYL ACCIDENT; CONTROLLED STUDY; DNA REPAIR; DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RADIATION EXPOSURE; TRANSITIONAL CELL CARCINOMA; UKRAINE; URINARY EXCRETION; UROTHELIUM;

EID: 0032992458     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00727.x     Document Type: Article

References (40)

1. Boring, C. C., Squires, T. S. and Tong, T. Cancer statistics. CA Cancer J. Clin., 41, 19-36 (1991).
2. Richmond, C. R. Accelerating the turnover of internally deposited radiocesiuni. In "Diagnosis and Treatment of Deposited Radionuclides," ed. H. A. Kornberg and W. D. Norwood, pp. 315-325 (1968). Excerpta Medical Foundation. Battelle-Northwest Richland, WA.
3. Rundo, J., Mason, J., Newton, D. and Taylor, B. T. Biological half-life of cesium in man in acute and chronic exposure. Nature, 200, 188-189 (1963).
4. Vozianov, A. F., Romanenko, A. M. Wester, K. and Busch, C. Long-term low-dose irradiation and urothelium in patients with chronic cystitis. J. Acad. Med. Sci. Ukraine, 2, 421-436 (1996).
5. Cohen, S. M. and Ellwein, L. B. Genetic errors, cell proliferation and carcinogenesis. Cancer Res., 51, 6493-6505 (1991).
6. Kroft, S. H. and Oyasu, R. Biology of disease. Urinary bladder cancer: mechanisms of development and progression. Lab. Invest., 71, 158-174 (1994).
7. Cohen, S. M. and Ellwein, L. B. Cell proliferation in carcinogenesis. Science, 249, 1007-1011 (1990).
8. Tahara, E. Molecular mechanism of stomach carcinogenesis. J. Cancer Res. Clin. Oncol., 119, 265-272 (1993).
9. Masui, T., Don, I., Takada, N., Ogawa, K., Shirai, T. and Fukushima, S. p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 15, 2379-2381 (1994).
10. Simoneau, A. R. and Jones, P. A. Bladder cancer: the molecular progression to invasive disease. World J. Urol., 12, 89-95 (1994).
11. Yamamoto, S., Masui, T., Murai, T., Mori, S., Oohara, T., Makino, S., Fukushima, S. and Tatematsu, M. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NOH/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 16, 2363-2368 (1995).
12. Hashimoto, Y., Asamoto, M., Futakuchi, M., Okamura, T., Kohri, K. and Shirai, T. Immunohistochemical demonstration of p53 protein nuclear accumulation in preneoplastic and neoplastic lesions of the human urinary bladder. J. Urol. Pathol., 5, 21-27 (1996).
13. Renan, M. J. Point mutations, deletions and radiation carcinogenesis. Radiat. Res., 131, 227-228 (1992).
14. Kelman, Z. PCNA: structure, functions and interactions. Oncogene, 14, 629-640 (1997).
15. Hall, P. A., Levison, D. A., Woods, A. L., Yu, C. C.-W., Kellock, D. B., Watkins, J. A., Barnes, D. M., Gillet, C. E., Camplejohn, R., Dover, R., Waseem, N. H. and Lane, P. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J. Pathol., 162, 285-294 (1990).
16. Knuechel, R., Burgan, M., Rauschoff, J. and Hofstaedter, F. Proliferating cell nuclear antigen in normal urothelium and urothelial lesions of the urinary bladder: a quantitative assessment using a true colour image analysis system. Virchows Arch. B. Cell Pathol., 64, 137-144 (1993).
17. Hunter, T. and Pines, J. Cyclins and cancer II: cyclin D1 and CDK inhibitors come of age. Cell, 79, 573-582 (1994).
18. Jiang, W., Kahn, S. M., Zhou, P., Zhang, Y. I., Cacace, A. M., Infante, S. D., Santella, R. M. and Weinstein, I. B. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene, 8, 3447-3457 (1993).
19. Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T. and Furukawa, M. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res., 54, 3107-3110 (1994).
20. McIntosh, G. G., Anderson, J. J., Milton, I., Steward, M., Parr, A. H. and Thomas, M. D. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11, 885-891 (1995).
21. Betticher, D. C., Heighway, J., Hasleton, P. S., Altermatt, H. J. and Ryder, W. D. Prognostic significance of CCNDI (cyclin D1) overexpression in primary resected non-small cell lung cancer. Br. J. Cancer, 73, 294-300 (1996).
22. Arber, N., Doki, Y., Han, E. K.-H., Sgambato, A., Zhou, P., Kim, N., Delohery, T., Klein, M., Holt, P. and Weinstein, I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res., 57, 1569-1574 (1997).
23. Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N. and Beger, H. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res., 57, 1634-1637 (1997).
24. Nakagawa, H., Wang, T. C., Zukerberg, L., Odze, R., Togawa, K., May, G. H. W., Wilson, J. and Rustgi, A. K. The targeting of the cyclin D1 oncogene by an Epstein Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene, 14, 1185-1190 (1997).
25. Lee, C. C. R., Yamamoto, S., Morimura, K., Wanibuchi, H., Nishisaka, N., Ikemoto, S., Nakatani, T., Wada, S., Kishimoto, T. and Fukushima, S. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer, 79, 780-789 (1997).
26. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elladge, S. J. The p21 cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin dependent kinases. Cell, 75, 805-816 (1993).
27. Waga, S., Hannon, G. J., Beach, D. and Stilman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-578 (1994).
28. WAFl/Cipl expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919 (1995).
29. Romanenko, A., Vozianov, A., Wester, K. and Busch, Ch. Immunohistochemical changes in bladder urothelium of patients from radiocontaminated areas in Ukraine (a pilot study). Pathol. Res. Pract., 8, 763 (1995).
30. Friedell, G. H., Hawkins, I. R. and Nagy, G. K. Urinary bladder. In "The Pathology of Incipient Neoplasia," ed. D. E. Henson, J. Albores Saavedra et al., pp. 295-305 (1986). W.B. Saunders Co., Philadelphia, London, Toronto.
31. Malmstrom, P. U., Busch, C., Norlen, B. J. and Andersson, B. Expression of ABH blood group isoantigen as a prognostic factor in transitional cell bladder carcinoma. Scand. J. Urol. Nephrol. 22, 265-270 (1988).
32. Leadon, S. A. and Cooper, P. K. Preferential repair of ionizing radiation-induced damage in the transcribed strand of an active human gene is defective in Cockayne syndrome. Proc. Natl. Acad. Sci. USA, 90, 10499-10503 (1993).
33. Linke, S. P., Clarkin, K. C. and Wahl, G. M. p53 mediates permanent arrest over multiple cell cycles in response to irradiation. Cancer Res., 57, 1171-1179 (1997).
34. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71, 543-546 (1992).
35. McKay, B. C., Francis, M. A. and Rainblow, A. J. Wild type p53 is required for heat shock and ultraviolet light enhanced repair of UV-damaged reporter gene. Carcinogenesis, 18, 245-249 (1997).
36. Sal, G., Murphy, M., Ruaro, E. M., Lazarevic, D., Levine, A. J. and Schneider, C. Cyclin D1 and p21/WAF1 are both involved in p53 growth suppression. Oncogene, 12, 177-185 (1996).
37. Di Leonardo, A., Linke, S. P., Clarkin, K. and Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of CIP1 in normal human fibroblasts. Genes Dev., 8, 2540-2551 (1994).
38. Michieli, P., Chedid, M., Lin, D., Piece, J. H., Mercer, W. E. and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391-3395 (1994).
39. Gadbois, D. M., Bradbury, E. M. and Lehnert, B. E. Control of radiation-induced G1 arrest by cell-substratum interactions. Cancer Res., 57, 1151-1156 (1997).
40. Lee, C. C. R., Yamamoto, S., Wanibuchi, H., Wada, S., Sugimura, K., Kishimoto, T. and Fukushima, S. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res., 57, 4765-4776 (1997).